Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

29

Revenue 2017

Soliris

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Soliris was produced by Alexion.

Drug launches to watch in 2019

Drug launches to watch in 2019

Analysts predict peak sales of up to $3bn. 5. Ultomiris – Alexion’s follow-up to Soliris. ... The drug matched Soliris for efficacy with a trend towards superiority and has improved dosing.

Alexion targets RNAi with $637m Dicerna deal

Alexion targets RNAi with $637m Dicerna deal Alexion already has a follow-on complement inhibitor to be the next generation replacement for Soliris. ... With Soliris, Alexion has demonstrated the transformative impact of complement inhibition on multiple serious and debilitating diseases.

Alexion adds to pipeline with $1.2bn Syntimmune buy

Alexion adds to pipeline with $1.2bn Syntimmune buy Alexion is in the midst of a concerted effort to build its pipeline as it prepares for the possible loss of patent protection for Soliris (eculizumab), its biggest-selling product. ... Used to treat paroxysmal nocturnal haemoglobinuria (PNH) and

The year of the blockbuster

The year of the blockbuster These include Juno Therapeutics’ CAR T-cell therapy, lisocabtagene maraleucel, for diffuse large B-cell lymphoma, and Alexion’s next-generation Soliris treatment, ravulizumab, for paroxysmal nocturnal haemoglobinuria.

Alexion uses priority review voucher for Soliris follow-up

Alexion uses priority review voucher for Soliris follow-up Files ravulizumab for paroxysmal nocturnal haemoglobinuria. Alexion is pulling out all the stops to get speedy approval for a follow-up to its rare blood disorder therapy Soliris, using a coveted ... The company has filed ravulizumab ( ALXN1210) for

1 2 3 4 5 6 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics